Dr. Lorch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
676 N St Clair St
Chicago, IL 60611Phone+1 312-695-6180Fax+1 312-695-6189
Education & Training
University of RegensburgClass of 1994
Certifications & Licensure
IL State Medical License 1999 - 2026
MA State Medical License 2005 - 2022
ME State Medical License 2020 - 2021
PA State Medical License 1997 - 1999
Clinical Trials
- A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Roles: Principal Investigator
Publications & Presentations
PubMed
- 424 citationsCDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries
Cancer Discovery. 2017-11-03 - 93 citationsThe Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.Vivek Kumar, Atul B. Shinagare, Helmut G. Rennke, Sandeep Ghai, Jochen H. Lorch
The Oncologist. 2020-02-11 - 40 citationsThe Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer.Nathalie Anne de Oliveira e Silva de Morais, Jessica Stuart, Haixia Guan, Zhihong Wang, Edmund S. Cibas
Journal of the Endocrine Society. 2019-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
